Liu Jingjing, Bi Minghong
Department of Medical Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
Zhongguo Fei Ai Za Zhi. 2013 Nov;16(11):615-20. doi: 10.3779/j.issn.1009-3419.2013.11.11.
Lung cancer is the leading cause of cancer-related death worldwide, molecular target therapy has become a hot research direction of non-small cell lung cancer (NSCLC) treatment. RET fusion gene with an identifiable clinical pathological features, is present in some subsets of lung cancer, and its treatment is effective by RET inhibitor, suggesting that RET fusion gene may be a new target for individualized treatment to the subgroup of NSCLC. This article reviews the structural characteristics of RET fusion gene and expression model in clinical samples, and treatment of NSCLC.
肺癌是全球癌症相关死亡的主要原因,分子靶向治疗已成为非小细胞肺癌(NSCLC)治疗的热门研究方向。RET融合基因具有可识别的临床病理特征,存在于部分肺癌亚组中,且其治疗可通过RET抑制剂实现有效,这表明RET融合基因可能是NSCLC亚组个体化治疗的新靶点。本文综述了RET融合基因的结构特征、在临床样本中的表达模式以及NSCLC的治疗情况。